ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

AstraZeneca and Regeneron Pharmaceuticals side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

AstraZenecaRegeneron Pharmaceuticals
studies on the registry4,197413
open to participants now29883
phase 3 studies under way20038
reach primary completion within a year16930
programswith a study of their own in two years119+5 named only43

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseAstraZenecaRegeneron Pharmaceuticals
Phase 1

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Regeneron Pharmaceuticals: 8 of its 43 programs at phase 1

  1. REGN9533phase 1
  2. ALN-SNCAphase 1
  3. REGN17235phase 1
  4. REGN20423phase 1
  5. REGN20934phase 1

and 3 more — sign in to see them all

19%
Phase 2

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%

Regeneron Pharmaceuticals: 16 of its 43 programs at phase 2

  1. ALN-PNPphase 2
  2. vonsetamigphase 2
  3. ALN-ANG3phase 2
  4. olsutamigphase 2
  5. ubamatamabphase 2

and 11 more — sign in to see them all

37%
Phase 3

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Regeneron Pharmaceuticals: 15 of its 43 programs at phase 3

  1. cemiplimabphase 3
  2. cenvacibartphase 3
  3. fianlimabphase 3
  4. odronextamabphase 3
  5. amrecibartphase 3

and 10 more — sign in to see them all

35%
Approved, new studies

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Regeneron Pharmaceuticals: 4 of its 43 programs at approved, new studies

  1. linvoseltamabapproved, new study
  2. pozelimabapproved, new study
  3. dupilumabapproved, new study
  4. alirocumabapproved, new study
9%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
AstraZeneca61 readouts · 16 phase 3

AstraZeneca, Nov ’26: 6 programs whose next study reaches primary completion

  1. elecoglipronphase 3 · Nov 18 · NCT07723833
  2. Elecoglipron Test formulation 1 Dose Aphase 1 · Nov 18 · NCT07723833
  3. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  4. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  5. durvalumabapproved, new study · Nov 30 · NCT07081633

and 1 more — sign in to see them all

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 12 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 7 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Regeneron Pharmaceuticals14 readouts · 4 phase 3·

Regeneron Pharmaceuticals, Dec ’26: 2 programs whose next study reaches primary completion

  1. ALN-ANG3phase 2 · Dec 4 · NCT06452771
  2. alirocumabapproved, new study · Dec 29 · NCT07477704

Regeneron Pharmaceuticals, Jan ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. fianlimabphase 3 · Jan 15 · NCT05608291

Regeneron Pharmaceuticals, Feb ’27: 4 programs whose next study reaches primary completion

  1. REGN22044phase 1 · Feb 8 · NCT07526116
  2. amrecibartphase 3 · Feb 9 · NCT07175428
  3. cenvacibartphase 3 · Feb 9 · NCT07175428
  4. REGN20934phase 1 · Feb 22 · NCT07594093

Regeneron Pharmaceuticals, Mar ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. cemiplimabphase 3 · Mar 22 · NCT06246916

Regeneron Pharmaceuticals, Apr ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. REGN9533phase 1 · Apr 2 · NCT07759167
  2. dupilumabapproved, new study · Apr 24 · NCT06572228
·

Regeneron Pharmaceuticals, Jun ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. mibavademabphase 3 · Jun 18 · NCT07220772
·

Regeneron Pharmaceuticals, Aug ’27: 3 programs whose next study reaches primary completion

  1. ALN-PNPphase 2 · Aug 10 · NCT05648214
  2. ALN-CIDEBphase 3 · Aug 17 · NCT06836609
  3. linvoseltamabapproved, new study · Aug 31 · NCT06369467
··
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 20, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Regeneron Pharmaceuticals

New programs 5

  • REGN9220phase 2 · first study · Oct 14 · Lymphoma, Large B-Cell, Diffuse
  • REGN13089phase 2 · first study · Oct 2 · Carcinoma, Renal Cell
  • REGN24493phase 1 · first study · Sep 30 · Graves Disease
  • REGN21353phase 2 · first study · Sep 23 · Prostatic Neoplasms
  • ALN-6457phase 2 · first study · Sep 16 · Dementia

Reached a new phase 2

Study stopped 0

None

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 39 in all, the first 12 here. A program counts in each condition its studies name most.

ConditionAstraZenecaRegeneron Pharmaceuticals
Carcinoma, Non-Small-Cell Lungboth · compare here

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 18 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 13 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Regeneron Pharmaceuticals in Carcinoma, Non-Small-Cell Lung: 3 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3
  3. ubamatamabphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Non-Small-Cell Lung in search

Prostatic Neoplasmsboth · compare here

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Regeneron Pharmaceuticals in Prostatic Neoplasms: 2 programs

  1. olsutamigphase 2
  2. REGN21353phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Prostatic Neoplasms in search

Asthmaboth · compare here

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Regeneron Pharmaceuticals in Asthma: 1 program

  1. dupilumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Asthma in search

Obesityboth · compare here

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Regeneron Pharmaceuticals in Obesity: 5 programs

  1. ALN-CIDEBphase 3
  2. olatorepatidephase 3
  3. mibavademabphase 3
  4. garetosmabphase 3
  5. REGN20934phase 1

Their studies: Regeneron Pharmaceuticals’ studies of Obesity in search

Pulmonary Disease, Chronic Obstructiveboth · compare here

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Regeneron Pharmaceuticals in Pulmonary Disease, Chronic Obstructive: 1 program

  1. dupilumabapproved, new study

Their studies: Regeneron Pharmaceuticals’ studies of Pulmonary Disease, Chronic Obstructive in search

Renal Insufficiency, Chronicboth · compare here

AstraZeneca in Renal Insufficiency, Chronic: 8 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. Berzanoflastphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency, Chronic in search

Regeneron Pharmaceuticals in Renal Insufficiency, Chronic: 1 program

  1. vonsetamigphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Renal Insufficiency, Chronic in search

Heart Failureboth · compare here

AstraZeneca in Heart Failure: 6 programs

  1. elecoglipronphase 3
  2. baxdrostatphase 3
  3. balcinrenonephase 3
  4. Pexerelgonphase 2
  5. dapagliflozinapproved, new study

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Heart Failure in search

Regeneron Pharmaceuticals in Heart Failure: 1 program

  1. vixticibartphase 2

Their studies: Regeneron Pharmaceuticals’ studies of Heart Failure in search

Neoplasmsboth · compare here

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Regeneron Pharmaceuticals in Neoplasms: 1 program

  1. fianlimabphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Neoplasms in search

Squamous Cell Carcinoma of Head and Neckboth · compare here

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 5 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. volrustomigphase 3
  4. monalizumabphase 3
  5. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Regeneron Pharmaceuticals in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. cemiplimabphase 3
  2. fianlimabphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Squamous Cell Carcinoma of Head and Neck in search

Carcinoma, Renal Cellboth · compare here

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

Regeneron Pharmaceuticals in Carcinoma, Renal Cell: 3 programs

  1. olsutamigphase 2
  2. Anti-PSMA/Anti-4-1BB Bispecific Antibody REGN15505phase 2
  3. REGN13089phase 2

Their studies: Regeneron Pharmaceuticals’ studies of Carcinoma, Renal Cell in search

Diabetes Mellitus, Type 2both · compare here

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Regeneron Pharmaceuticals in Diabetes Mellitus, Type 2: 1 program

  1. olatorepatidephase 3

Their studies: Regeneron Pharmaceuticals’ studies of Diabetes Mellitus, Type 2 in search

Lymphoma, Follicularboth · compare here

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Regeneron Pharmaceuticals in Lymphoma, Follicular: 1 program

  1. odronextamabphase 3

Their studies: Regeneron Pharmaceuticals’ studies of Lymphoma, Follicular in search

Show all 39

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: AstraZeneca 68 of 119 · Regeneron Pharmaceuticals 17 of 43 programs (45 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).